MORRIS PLAINS, N.J., June 1, 2010 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that nine presentations will be given at the 57th Annual Meeting of the Society of Nuclear Medicine (SNM), scheduled for June 5 – 9, 2010, in Salt Lake City, UT. The schedule and meeting places for the oral presentations and scientific poster sessions, together with the publication numbers are listed below:
-
"Pretargeted immunoPET for imaging human colonic cancer in a mouse model" [Publication No. 61, Scientific Paper Session (Oral), Session Info: Nuclear Oncology Council Young Investigator Award Symposium, Sunday, June 6, 5:15 p.m. – 5:27 p.m., Room Ballroom I]
-
"Rapid, one-step, high-specific activity, radiolabeling of peptides with F-18 without HPLC purification" [Publication No. 136, Scientific Paper Session (Oral), Session Info: New Radiopharmaceuticals – Broader/General Applications I, Monday, June 7, 11:12 a.m. – 11:24 a.m., Room Ballroom E]
-
"Combination 90Y-hPAM4 radioimmunotherapy (RAIT) and anti-epithelial glycoprotein-1 (EGP-1)-SN-38 antibody-drug conjugate (ADC) improves pancreatic cancer therapy without increasing toxicity" [Publication No. 174, Scientific Paper Session (Oral), Session Info: Oncology: Radiopharmaceutical Therapy - Radioimmunotherapy, Monday, June 7, 1:06 p.m. – 1:18 p.m., Room Ballroom I]
-
"Pretargeting a radiolabeled hapten-peptide with a tri-Fab humanized bispecific antibody (bsMAb) to CEACAM5: First results in patients with colorectal cancer" [Publication No. 176, Scientific Paper Session (Oral), Session Info: Oncology: Radiopharmaceutical Therapy - Radioimmunotherapy, Monday, June 7, 1:30 p.m. – 1:42 p.m., Room Ballroom I]
-
"A new and rapid method of labeling peptides with F-18" [Publication No. 198, Scientific Paper Session (Oral), Session Info: New Radiopharmaceuticals – Novel Probe Development I: Peptides, Monday, June 7, 1:42 p.m. – 1:54 p.m., Room Ballroom E]
-
"Pretargeted immunoPET imaging and radioimmunotherapy (RIT) of prostate cancer with an anti-EGP1 x anti-HSG bispecific antibody (bsMAb)" [Publication No. 501, Scientific Paper Session (Oral), Session Info: Oncology: translational/Preclinical Nuclear Medicine – Antibodies, Integrins, Wednesday June 9, 8:12 a.m. – 8:24 a.m., Room Ballroom I]
-
"Pretargeted radioimmunotherapy (PT-RAIT) of CEA-expressing tumors in nude mice with subcutaneous and intraperitoneal human tumor xenografts" [Publication No. 503, Scientific Paper Session (Oral), Session Info: Oncology: translational/Preclinical Nuclear Medicine – Antibodies, Integrins, Wednesday, June 9, 8:36 a.m. – 8:48 a.m., Room Ballroom I]
-
"A new tri-Fab recombinant bispecific antibody (bsMAb) for pretargeting epithelial cancers: Studies with TF12 and 111In-labeled hapten-peptide (IMP 288) in ovarian cancer" [Publication No. 1148, Scientific Poster Session, Poster Section: Oncology: Image Guided Therapy Posters, Monday June 7, 2:30 p.m. – 3:15 p.m., Exhibit Hall E]
- "Evaluation of 68Ga/68Ge generator and preparation of a 68Ga-DOTA-hapten-peptide for bispecific antibody (bsMAb) pretargeting" [Publication No. 1526, Scientific Poster Session, Poster Section: New Radiopharmaceuticals - Oncology Posters, Tuesday, June 8, 2:30 p.m. – 3:15 p.m., Exhibit Hall E]
About Immunomedics
Immunomedics is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or "naked" form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents. Using these technologies, we have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. We also have a majority ownership in IBC Pharmaceuticals, Inc., which is developing a novel Dock-and-Lock (DNL) methodology with us for making fusion proteins and multifunctional antibodies, and a new method of delivering imaging and therapeutic agents selectively to disease, especially different solid cancers (colorectal, lung, pancreas, etc.), by proprietary, antibody-based, pretargeting methods. We believe that our portfolio of intellectual property, which includes approximately 149 patents issued in the United States and more than 375 other patents issued worldwide, protects our product candidates and technologies. For additional information on us, please visit our website at www.immunomedics.com. The information on our website does not, however, form a part of this press release.
This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials, out-licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating results, and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, risks associated with new product development (including clinical trials outcome and regulatory requirements/actions), our dependence on our licensing partners for the further development of epratuzumab for autoimmune indications and veltuzumab for non-cancer indications, competitive risks to marketed products and availability of required financing and other sources of funds on acceptable terms, if at all, as well as the risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Immunomedics, Inc.
Dr. Chau Cheng, Associate Director,
Investor Relations & Business Analysis
(973) 605-8200, extension 123
ccheng@immunomedics.com
